Clinical Trial Update: Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vorolanib in combination with sintilimab for advanced renal cell carcinoma after prior immune checkpoint inhibitor therapy; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)
• Vorolanib (vorolanib)

Snippet

Sponsor: Hao Zeng | Conditions: Renal Cell Carcinoma, Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING